Metropolis Healthcare Q4FY26 Revenue Grows ~23% YoY on Strong Wellness, Specialty Demand

METROPOLIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.9%1-day move

₹422.90

prior close

₹433.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.1-1.3-1.6-2.0+1.9+7.6+8.1+10.0+10.0+11.6+13.5+21.0+24.6+35.5

Up moveDown movePending

AI summary

Metropolis Healthcare reported Q4FY26 consolidated revenue growth of ~23% YoY, driven by strong traction in TruHealth wellness (+~25%) and specialty testing (+~29%). B2B revenue grew ~30% and B2C ~19% YoY. Organic revenue grew ~14.5% YoY. Recent acquisitions (Core Diagnostics, DAPIC, Scientific, Ambika) are performing well with margins improving. Core Diagnostics margins reached high single-digit range. Detailed financials are pending board approval and audit.

Likely market impact

Strong topline growth across all segments signals robust demand and successful acquisition integration. Positive for investor sentiment; audited results awaited.